The listing price prediction of Anthem Biosciences IPO is Rs 727, this translates a percentage of 27.54 per cent. On the last ...

Since this IPO was fully an OFS, the contract research, development and manufacturing company will not receive any funds, ...

The SC found grave lapses in the investigation, particularly in the handling of DNA evidence, the conduct of post-mortem ...

Anthem Biosciences' initial public offering (IPO) was subscribed 63.86 times, largely due to strong support from qualified institutional buyers (QIBs).

Anthem Biosciences IPO oversubscribed 63.86 times, attracting strong QIB support, raising ₹1,016 crore from anchor investors.

Recent health headlines include FDA's eye safety concerns over GSK's cancer drug, escalating malnutrition rates in Gaza ...

Anthem Biosciences’ ₹3,395-crore IPO saw strong investor demand, with overall subscription at 63.86x, signaling robust interest in the pharma CDMO sector.

Anthem Biosciences' IPO ended on 16 July, with the issue booked over 60 times. Strong demand from qualified institutional ...

Anthem Biosciences' Rs 3,395 crore IPO was subscribed 63.86 times, exceeding expectations. QIBs showed strong interest, while ...

Anthem Biosciences Ltd's IPO was subscribed 63.86 times by closing day, driven by institutional buyers. The Rs 3,395-crore ...

To distribute and promote Emcure's oral anti-diabetic (OAD) products in India Emcure Pharmaceuticals (Emcure) and Sanofi India (SIL) today entered into an exclusive distribution and promotion ...

Following the close of the subscription of initial public offering (IPO) of Anthem Biosciences Limited, all eyes of the ...